AVCT.L

Avacta Group Plc
Avacta Group PLC - Director/PDMR Shareholdings and TVR
2nd September 2024, 14:53
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5844C
Avacta Group PLC
02 September 2024
 

2 September 2024

Avacta Group plc

("Avacta", the "Group" or the "Company")

 

Director/PDMR Shareholdings

and

Total Voting Rights

 

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that a total of 3,600,000 options over ordinary shares of 10p each ("Ordinary Shares") were granted to Christina Coughlin, MD, PhD, Chief Executive Officer (the "Options") on 30 August 2024.

 

The Options were granted under the Company's Long Term Incentive Plan, Avacta Group plc Executive Share Option Scheme and are time-based, vesting in three equal tranches over three years to 1 May 2027. The exercise price of the Options is 72p, being the closing mid-market share price of the Company's ordinary shares on the 29 August 2024.

 

Also on 30 August 2024, Tony Gardiner, CFO, exercised 500,000 options and sold the resulting ordinary shares of 10p each at an average price of 71.07 pence per share.  The exercise price of the options was 10p per ordinary share. Tony Gardiner continues to retain 2,328,324 options over Ordinary Shares. 

 

As previously announced Tony Gardiner stepped down from the Board on 26 June 2024 but will be remaining as CFO until 31st October 2024 whilst the search for a new permanent CFO is undertaken.

 

Following the allotment of the 500,000 ordinary shares issued as a result of the exercise of options by Tony Gardiner, the Company's enlarged issued share capital is 362,159,730 ordinary shares of 10p each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Christina Coughlin, CEO

Michael Vinegrad, Group Communications Director

 

Tel: +44 (0) 1904 21 7070

www.avacta.com

Peel Hunt (Nomad and Broker)

James Steel / Chris Golden / Patrick Birkholm

 

www.peelhunt.com

ICR Consilium

Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

avacta@consilium-comms.com

 

 

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

 

Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.

 

Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics.

 

Avacta has two proprietary platforms, pre|CISION™ and Affimer®.

 

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.

 

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.

 

 

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.           

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Christina Coughlin

2.           

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.  

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4.  

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Options over Ordinary Shares

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

Grant of Options over Ordinary Shares

 

c)

Price(s) and volume(s)

 

LTIP

Exercise Price(s)

Volume(s)

72.00 pence

3,600,000

d)

Aggregated information:

·      Aggregated volume

·      Price

As above

e)

Date of the transaction

30 August 2024

f)

Place of the transaction

Outside a trading venue

 

 

1.  

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Tony Gardiner

2.           

Reason for the Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3.  

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4.  

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Ordinary Shares

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

Exercise of Options over Ordinary Shares

 

c)

Price(s) and volume(s)

 

LTIP

Exercise Price(s)

Volume(s)

10.0 pence

500,000

d)

Aggregated information:

·      Aggregated volume

·      Price

As above

e)

Date of the transaction

30 August 2024

f)

Place of the transaction

Outside a trading venue

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Tony Gardiner

2.

Reason for the Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Ordinary Shares

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

Sale of Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

71.07 pence

500,000

d)

Aggregated information:

·      Aggregated volume

·      Price

As above

e)

Date of the transaction

30 August 2024

f)

Place of the transaction

London Stock Exchange, AIM Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUUSSRSKUKRAR]]>
TwitterFacebookLinkedIn